Back to Search Start Over

Regulator of G-protein signaling 5 enhances portal vein invasion in hepatocellular carcinoma.

Authors :
Umeno Y
Ogasawara S
Akiba J
Hattori S
Kusano H
Nakashima O
Koga H
Torimura T
Yamakawa R
Yano H
Source :
Oncology letters [Oncol Lett] 2018 Feb; Vol. 15 (2), pp. 1763-1770. Date of Electronic Publication: 2017 Nov 23.
Publication Year :
2018

Abstract

Portal vein invasion (PVI) is a major prognostic factor in hepatocellular carcinoma (HCC). The aim of the present study was to identify molecules that regulate PVI. Sections of cancerous tissue, paired noncancerous tissue and the PVI area were collected from 3 frozen HCC sections, using laser microdissection. The present study focused on 3 upregulated molecules, integrin β3 (ITGB3), secreted phosphoprotein 1 (SPP1) and regulator of G-protein signaling 5 (RGS5), and 2 molecules that were downregulated in PVI tissue compared with cancer tissue, metallothionein 1G (MT1G) and metallothionein 1H (MT1H), as determined by cDNA microarray analysis. Reverse transcription-quantitative polymerase chain reaction analysis of 32 HCC cases revealed that RGS5 mRNA levels were significantly increased and MT1 G and MT1H mRNA levels were significantly decreased in cancerous tissue compared with noncancerous tissue. However, there was no significant difference in ITGB3 and SPP1 expression. There were no significant differences between the expression of these molecules and any clinicopathologic factors, including PVI. Immunohistochemical staining for RGS5 in 60 HCC cases demonstrated that RGS5 protein levels were higher in cancerous tissue compared with paired noncancerous tissue in 63.3% of HCC cases. Furthermore, high expression of RGS5 in cancerous tissue was significantly associated with PVI and tended to be associated with intrahepatic metastasis. Confluent multinodular type was significantly more frequent in cases with high expression of RGS5 in the cancerous tissue. Therefore, RGS5 may be a useful prognostic biomarker as well as a potential target of molecular therapy to treat HCC.

Details

Language :
English
ISSN :
1792-1074
Volume :
15
Issue :
2
Database :
MEDLINE
Journal :
Oncology letters
Publication Type :
Academic Journal
Accession number :
29434872
Full Text :
https://doi.org/10.3892/ol.2017.7474